A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Natalizumab is an antagonist of α 4 integrin, a very late adhesion antigen that is expressed on the surface of activated lymphocytes and monocytes. In this double-blind, placebo-controlled trial, the patients who received natalizumab had fewer new enhancing lesions on gadolinium-enhanced magnetic re...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2003-01, Vol.348 (1), p.15-23 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1 |
| container_start_page | 15 |
| container_title | The New England journal of medicine |
| container_volume | 348 |
| creator | Miller, David H Khan, Omar A Sheremata, William A Blumhardt, Lance D Rice, George P.A Libonati, Michele A Willmer-Hulme, Allison J Dalton, Catherine M Miszkiel, Katherine A O'Connor, Paul W |
| description | Natalizumab is an antagonist of α
4
integrin, a very late adhesion antigen that is expressed on the surface of activated lymphocytes and monocytes. In this double-blind, placebo-controlled trial, the patients who received natalizumab had fewer new enhancing lesions on gadolinium-enhanced magnetic resonance imaging and significantly fewer relapses.
Treatment with agents that inhibit adhesion of activated immune cells may offer benefits.
Multiple sclerosis is a leading cause of chronic neurologic disability.
1
Several new therapies have been introduced in the past decade,
2
–
5
but additional effective treatments are needed to slow disease progression and reduce disability. The pathological hallmark of multiple sclerosis is multiple foci of inflammation and demyelination within the white matter of the central nervous system. The formation of these lesions may involve lymphocytes and monocytes that gain access to the brain parenchyma from the circulation by first adhering to vascular endothelial cells in regions of inflammation.
6
The glycoprotein α
4
β
1
integrin, also known as very late antigen . . . |
| doi_str_mv | 10.1056/NEJMoa020696 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_220162400</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>273504301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-4b331a38e218243a80fd1d0c09eb1277e9099ba700d15fe9a5f6054a55a2e5bc3</originalsourceid><addsrcrecordid>eNptkLtOw0AQRVcIREKgo0YWgg7D7MuPMkThpSRIEGprbK-Ro7XX7NoFfD2GWAoF00xzdM_MJeSUwjUFGdys5k9Lg8AgiIM9MqaSc18ICPbJGIBFvghjPiJHzm2gHyriQzKiTFIAHo3J7dSbmbq1RmuVe2tbovZM4a2wRV1-dRWmXmGs96I0Nq6s371lp9uy0cp7zbSyxpXumBwUqJ06GfaEvN3N17MHf_F8_zibLvxMBqz1Rco5RR4pRiMmOEZQ5DSHDGKVUhaGKoY4TjEEyKksVIyyCEAKlBKZkmnGJ-R8m9tY89Ep1yYb09m6VyaMAQ2Y6F-akKstlPW3OauKpLFlhfYzoZD89JX87avHz4bMLq1UvoOHgnrgcgDQZagLi3VWuh0nRCCiX-_Flqsql9RqU_3v-wYxF3wS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220162400</pqid></control><display><type>article</type><title>A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Miller, David H ; Khan, Omar A ; Sheremata, William A ; Blumhardt, Lance D ; Rice, George P.A ; Libonati, Michele A ; Willmer-Hulme, Allison J ; Dalton, Catherine M ; Miszkiel, Katherine A ; O'Connor, Paul W</creator><creatorcontrib>Miller, David H ; Khan, Omar A ; Sheremata, William A ; Blumhardt, Lance D ; Rice, George P.A ; Libonati, Michele A ; Willmer-Hulme, Allison J ; Dalton, Catherine M ; Miszkiel, Katherine A ; O'Connor, Paul W ; International Natalizumab Multiple Sclerosis Trial Group</creatorcontrib><description>Natalizumab is an antagonist of α
4
integrin, a very late adhesion antigen that is expressed on the surface of activated lymphocytes and monocytes. In this double-blind, placebo-controlled trial, the patients who received natalizumab had fewer new enhancing lesions on gadolinium-enhanced magnetic resonance imaging and significantly fewer relapses.
Treatment with agents that inhibit adhesion of activated immune cells may offer benefits.
Multiple sclerosis is a leading cause of chronic neurologic disability.
1
Several new therapies have been introduced in the past decade,
2
–
5
but additional effective treatments are needed to slow disease progression and reduce disability. The pathological hallmark of multiple sclerosis is multiple foci of inflammation and demyelination within the white matter of the central nervous system. The formation of these lesions may involve lymphocytes and monocytes that gain access to the brain parenchyma from the circulation by first adhering to vascular endothelial cells in regions of inflammation.
6
The glycoprotein α
4
β
1
integrin, also known as very late antigen . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa020696</identifier><identifier>PMID: 12510038</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Brain - pathology ; Cell adhesion & migration ; Double-Blind Method ; Female ; Gadolinium ; Humans ; Magnetic Resonance Imaging ; Male ; Medical research ; Medical sciences ; Middle Aged ; Multiple sclerosis ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - pathology ; Natalizumab ; Neurology ; Neuropharmacology ; Neuroprotective agent ; NMR ; Nuclear magnetic resonance ; Pharmacology. Drug treatments ; Statistics, Nonparametric</subject><ispartof>The New England journal of medicine, 2003-01, Vol.348 (1), p.15-23</ispartof><rights>Copyright © 2003 Massachusetts Medical Society. All rights reserved.</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-4b331a38e218243a80fd1d0c09eb1277e9099ba700d15fe9a5f6054a55a2e5bc3</citedby><cites>FETCH-LOGICAL-c562t-4b331a38e218243a80fd1d0c09eb1277e9099ba700d15fe9a5f6054a55a2e5bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa020696$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa020696$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14464800$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12510038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, David H</creatorcontrib><creatorcontrib>Khan, Omar A</creatorcontrib><creatorcontrib>Sheremata, William A</creatorcontrib><creatorcontrib>Blumhardt, Lance D</creatorcontrib><creatorcontrib>Rice, George P.A</creatorcontrib><creatorcontrib>Libonati, Michele A</creatorcontrib><creatorcontrib>Willmer-Hulme, Allison J</creatorcontrib><creatorcontrib>Dalton, Catherine M</creatorcontrib><creatorcontrib>Miszkiel, Katherine A</creatorcontrib><creatorcontrib>O'Connor, Paul W</creatorcontrib><creatorcontrib>International Natalizumab Multiple Sclerosis Trial Group</creatorcontrib><title>A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Natalizumab is an antagonist of α
4
integrin, a very late adhesion antigen that is expressed on the surface of activated lymphocytes and monocytes. In this double-blind, placebo-controlled trial, the patients who received natalizumab had fewer new enhancing lesions on gadolinium-enhanced magnetic resonance imaging and significantly fewer relapses.
Treatment with agents that inhibit adhesion of activated immune cells may offer benefits.
Multiple sclerosis is a leading cause of chronic neurologic disability.
1
Several new therapies have been introduced in the past decade,
2
–
5
but additional effective treatments are needed to slow disease progression and reduce disability. The pathological hallmark of multiple sclerosis is multiple foci of inflammation and demyelination within the white matter of the central nervous system. The formation of these lesions may involve lymphocytes and monocytes that gain access to the brain parenchyma from the circulation by first adhering to vascular endothelial cells in regions of inflammation.
6
The glycoprotein α
4
β
1
integrin, also known as very late antigen . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Brain - pathology</subject><subject>Cell adhesion & migration</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Gadolinium</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - pathology</subject><subject>Natalizumab</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Neuroprotective agent</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Pharmacology. Drug treatments</subject><subject>Statistics, Nonparametric</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkLtOw0AQRVcIREKgo0YWgg7D7MuPMkThpSRIEGprbK-Ro7XX7NoFfD2GWAoF00xzdM_MJeSUwjUFGdys5k9Lg8AgiIM9MqaSc18ICPbJGIBFvghjPiJHzm2gHyriQzKiTFIAHo3J7dSbmbq1RmuVe2tbovZM4a2wRV1-dRWmXmGs96I0Nq6s371lp9uy0cp7zbSyxpXumBwUqJ06GfaEvN3N17MHf_F8_zibLvxMBqz1Rco5RR4pRiMmOEZQ5DSHDGKVUhaGKoY4TjEEyKksVIyyCEAKlBKZkmnGJ-R8m9tY89Ep1yYb09m6VyaMAQ2Y6F-akKstlPW3OauKpLFlhfYzoZD89JX87avHz4bMLq1UvoOHgnrgcgDQZagLi3VWuh0nRCCiX-_Flqsql9RqU_3v-wYxF3wS</recordid><startdate>20030102</startdate><enddate>20030102</enddate><creator>Miller, David H</creator><creator>Khan, Omar A</creator><creator>Sheremata, William A</creator><creator>Blumhardt, Lance D</creator><creator>Rice, George P.A</creator><creator>Libonati, Michele A</creator><creator>Willmer-Hulme, Allison J</creator><creator>Dalton, Catherine M</creator><creator>Miszkiel, Katherine A</creator><creator>O'Connor, Paul W</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20030102</creationdate><title>A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis</title><author>Miller, David H ; Khan, Omar A ; Sheremata, William A ; Blumhardt, Lance D ; Rice, George P.A ; Libonati, Michele A ; Willmer-Hulme, Allison J ; Dalton, Catherine M ; Miszkiel, Katherine A ; O'Connor, Paul W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-4b331a38e218243a80fd1d0c09eb1277e9099ba700d15fe9a5f6054a55a2e5bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Brain - pathology</topic><topic>Cell adhesion & migration</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Gadolinium</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - pathology</topic><topic>Natalizumab</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Neuroprotective agent</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Pharmacology. Drug treatments</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, David H</creatorcontrib><creatorcontrib>Khan, Omar A</creatorcontrib><creatorcontrib>Sheremata, William A</creatorcontrib><creatorcontrib>Blumhardt, Lance D</creatorcontrib><creatorcontrib>Rice, George P.A</creatorcontrib><creatorcontrib>Libonati, Michele A</creatorcontrib><creatorcontrib>Willmer-Hulme, Allison J</creatorcontrib><creatorcontrib>Dalton, Catherine M</creatorcontrib><creatorcontrib>Miszkiel, Katherine A</creatorcontrib><creatorcontrib>O'Connor, Paul W</creatorcontrib><creatorcontrib>International Natalizumab Multiple Sclerosis Trial Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, David H</au><au>Khan, Omar A</au><au>Sheremata, William A</au><au>Blumhardt, Lance D</au><au>Rice, George P.A</au><au>Libonati, Michele A</au><au>Willmer-Hulme, Allison J</au><au>Dalton, Catherine M</au><au>Miszkiel, Katherine A</au><au>O'Connor, Paul W</au><aucorp>International Natalizumab Multiple Sclerosis Trial Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2003-01-02</date><risdate>2003</risdate><volume>348</volume><issue>1</issue><spage>15</spage><epage>23</epage><pages>15-23</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Natalizumab is an antagonist of α
4
integrin, a very late adhesion antigen that is expressed on the surface of activated lymphocytes and monocytes. In this double-blind, placebo-controlled trial, the patients who received natalizumab had fewer new enhancing lesions on gadolinium-enhanced magnetic resonance imaging and significantly fewer relapses.
Treatment with agents that inhibit adhesion of activated immune cells may offer benefits.
Multiple sclerosis is a leading cause of chronic neurologic disability.
1
Several new therapies have been introduced in the past decade,
2
–
5
but additional effective treatments are needed to slow disease progression and reduce disability. The pathological hallmark of multiple sclerosis is multiple foci of inflammation and demyelination within the white matter of the central nervous system. The formation of these lesions may involve lymphocytes and monocytes that gain access to the brain parenchyma from the circulation by first adhering to vascular endothelial cells in regions of inflammation.
6
The glycoprotein α
4
β
1
integrin, also known as very late antigen . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>12510038</pmid><doi>10.1056/NEJMoa020696</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2003-01, Vol.348 (1), p.15-23 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_220162400 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Brain - pathology Cell adhesion & migration Double-Blind Method Female Gadolinium Humans Magnetic Resonance Imaging Male Medical research Medical sciences Middle Aged Multiple sclerosis Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Natalizumab Neurology Neuropharmacology Neuroprotective agent NMR Nuclear magnetic resonance Pharmacology. Drug treatments Statistics, Nonparametric |
| title | A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T16%3A25%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Controlled%20Trial%20of%20Natalizumab%20for%20Relapsing%20Multiple%20Sclerosis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Miller,%20David%20H&rft.aucorp=International%20Natalizumab%20Multiple%20Sclerosis%20Trial%20Group&rft.date=2003-01-02&rft.volume=348&rft.issue=1&rft.spage=15&rft.epage=23&rft.pages=15-23&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa020696&rft_dat=%3Cproquest_cross%3E273504301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220162400&rft_id=info:pmid/12510038&rfr_iscdi=true |